PCM
FOLD

Peregrine Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Peregrine Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,084,278
Closed -$8.54M – 317
2025
Q3 		$8.54M Buy
1,084,278
+72,178
+7% +$514K 0.26% 105
2025
Q2 		$5.8M Buy
1,012,100
+101,592
+11% +$656K 0.17% 161
2025
Q1 		$7.43M Buy
910,508
+29,991
+3% +$278K 0.25% 114
2024
Q4 		$8.29M Buy
880,517
+135,716
+18% +$1.41M 0.25% 110
2024
Q3 		$7.95M Sell
744,801
-68,137
-8% -$742K 0.24% 109
2024
Q2 		$8.06M Buy
812,938
+79,389
+11% +$815K 0.24% 121
2024
Q1 		$8.64M Buy
733,549
+128,201
+21% +$1.64M 0.25% 112
2023
Q4 		$8.59M Sell
605,348
-123,337
-17% -$1.4M 0.26% 114
2023
Q3 		$8.86M Buy
728,685
+19,014
+3% +$245K 0.26% 134
2023
Q2 		$8.91M Sell
709,671
-86,893
-11% -$1.03M 0.24% 164
2023
Q1 		$8.83M Buy
796,564
+92,697
+13% +$1.14M 0.25% 168
2022
Q4 		$8.59M Sell
703,867
-108,494
-13% -$1.22M 0.27% 173
2022
Q3 		$8.48M Buy
812,361
+31,957
+4% +$356K 0.27% 169
2022
Q2 		$8.38M Sell
780,404
-46,916
-6% -$386K 0.25% 175
2022
Q1 		$7.83M Sell
827,320
-47,451
-5% -$445K 0.19% 218
2021
Q4 		$10.1M Buy
874,771
+164,919
+23% +$1.84M 0.2% 199
2021
Q3 		$6.78M Sell
709,852
-10,734
-1% -$110K 0.14% 241
2021
Q2 		$6.95M Buy
720,586
+30,799
+4% +$301K 0.12% 252
2021
Q1 		$6.82M Buy
689,787
+18,969
+3% +$294K 0.13% 252
2020
Q4 		$15.5M Sell
670,818
-312,479
-32% -$6.39M 0.29% 149
2020
Q3 		$13.9M Sell
983,297
-3,119
-0.3% -$45.5K 0.37% 104
2020
Q2 		$14.9M Sell
986,416
-273,691
-22% -$3.34M 0.42% 97
2020
Q1 		$11.6M Buy
1,260,107
+4,527
+0.4% +$43K 0.42% 99
2019
Q4 		$12.2M Buy
+1,255,580
New +$11.5M 0.31% 130

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Peregrine Capital Management's FOLD Position: Q4 2025 in Review

Peregrine Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 1,084,278 shares — an estimated $8.54M sold.

Peregrine Capital Management first reported a position in FOLD in Q4 2019 and held it in 24 quarters. The position peaked at $15.5M in Q4 2020. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Peregrine Capital Management reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 1,084,278 Amicus Therapeutics shares in Q4 2025, an estimated $8.54M.
  • Peregrine Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 24 quarters.
  • Peregrine Capital Management's Amicus Therapeutics position peaked at $15.5M in Q4 2020.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Peregrine Capital Management's 13F filing for Q4 2025, filed 28 Jan 2026.